Conrad Wai - Jul 22, 2025 Form 4 Insider Report for CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)

Role
CEO, Counterpart Health
Signature
/s/ Peter J. Rivas as attorney-in-fact for Conrad Wai
Stock symbol
CLOV
Transactions as of
Jul 22, 2025
Transactions value $
-$692,968
Form type
4
Date filed
7/24/2025, 04:11 PM
Previous filing
Jun 17, 2025
Next filing
Aug 4, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Wai Conrad CEO, Counterpart Health C/O CLOVER HEALTH INVESTMENTS, CORP., NOT APPLICABLE, WILMINGTON /s/ Peter J. Rivas as attorney-in-fact for Conrad Wai 2025-07-24 0001971702

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLOV Class A Common Stock Sale -$390K -119K -7.35% $3.29 1.49M Jul 22, 2025 By Trust. F1, F2
transaction CLOV Class A Common Stock Sale -$303K -91.2K -6.1% $3.32 1.4M Jul 23, 2025 By Trust. F2, F3
holding CLOV Class A Common Stock 1.7M Jul 22, 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.25 to $3.37, inclusive. The Reporting Person undertakes to provide to the SEC staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2 Shares held in trust for the benefit of the Reporting Person's family, of which the Reporting Person is a co-trustee.
F3 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.25 to $3.40, inclusive. The Reporting Person undertakes to provide to the SEC staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.